Bupropion
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
Bupropion: From Depression to Attention Deficit Hyperactivity Disorder
One-Sentence Summary
Bupropion is an antidepressant that is also used for smoking cessation, and it is registered in South Africa as an extended-release tablet. The TxGNN model predicts it may be effective for attention deficit hyperactivity disorder (ADHD), with 8 clinical trials and 19 publications currently supporting this direction, including one completed Phase 3 placebo-controlled trial and a Cochrane review. Note that the drug is not yet confirmed as the test agent in some of the larger trials.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Depression (from published literature; the SAHPRA indication text was blank in the data supplied) |
| Predicted New Indication | Attention deficit hyperactivity disorder |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L2 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 1 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the source record. From general pharmacology, bupropion is a norepinephrine-dopamine reuptake inhibitor. Unlike most antidepressants, it has no serotonergic activity. It raises dopamine and norepinephrine levels in the brain by blocking their reuptake.
ADHD is linked to reduced dopamine and norepinephrine signalling. Established ADHD drugs act on the same two pathways: stimulants promote catecholamine release, and atomoxetine blocks norepinephrine reuptake. This overlap explains why the model links bupropion to ADHD. Published reviews describe bupropion as a second-line or adjunct option, mainly for patients who do not respond to or cannot tolerate stimulants.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00048360 | Phase 3 | Completed | 162 | 8-week randomised, double-blind, placebo-controlled trial of flexible-dose extended-release bupropion (300–450 mg/day) in adults with ADHD. Results are not in the supplied data. The title is truncated, so confirm bupropion is the test agent. |
| NCT00061087 | Phase 2/3 | Completed | 115 | Treatment of adult ADHD in methadone-maintained patients. The drug and comparator are not named in the supplied text and should be verified at the registry. Strongest basis for L2. |
| NCT00936299 | Phase 4 | Completed | 105 | Bupropion for ADHD in adolescents with substance use disorder, a group usually excluded from medication trials. |
| NCT01270555 | Not applicable | Completed | 32 | Open-label study of bupropion SR in adults with ADHD and recent or current substance use disorders. Small, with no phase label. |
| NCT00000268 | Not applicable | Completed | 32 | Cocaine abuse with comorbid attention deficit disorder. Primary outcome is substance-use oriented. |
| NCT03326128 | Phase 2 | Terminated | 12 | High-dose bupropion for smoking cessation. Not an ADHD study. |
| NCT00330434 | Not applicable | Withdrawn | 0 | CYP2B6 pharmacokinetic study (ethanol and genetic variation). Not an ADHD efficacy study. |
| NCT04553263 | Early Phase 1 | Withdrawn | 0 | Relapse prevention in stimulant use disorder, with and without ADHD. Withdrawn, so no ADHD data. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 28965364 | 2017 | Cochrane systematic review | Cochrane Database Syst Rev | Bupropion for adult ADHD, as an alternative for adults who do not respond to or tolerate stimulants. The supplied excerpt does not state the results. |
| 30097390 | 2018 | Network meta-analysis | Lancet Psychiatry | Compares efficacy and tolerability of oral ADHD medications across children, adolescents and adults. |
| 33085721 | 2020 | Systematic review and network meta-analysis | PLoS One | Compares pharmacologic treatments for adult ADHD. |
| 38950507 | 2024 | Bayesian network meta-analysis | J Psychiatr Res | Efficacy and safety of monoamine reuptake inhibitors in ADHD, based on 31 clinical trials. |
| 27813651 | 2017 | Systematic review | J Child Adolesc Psychopharmacol | Bupropion in children and adolescents with ADHD, as a non-stimulant option for those who do not respond to stimulants. |
| 37405312 | 2023 | Review | Health Psychol Res | Pharmacology, mechanisms and interactions of bupropion across depression, ADHD and smoking cessation. |
| 40203844 | 2025 | Comparative safety study (design unverified) | Lancet Psychiatry | Cardiovascular safety of ADHD medications (blood pressure, heart rate, ECG parameters). |
| 38915262 | 2024 | Review | Expert Rev Neurother | Non-stimulant options for adults with ADHD when stimulants fail or are poorly tolerated. |
| 26693882 | 2016 | Systematic review | Expert Rev Neurother | Alternative drug strategies for adult ADHD in patients with partial or no response to standard drugs. |
| 26601963 | 2016 | Review | Curr Pharm Des | Lists bupropion among the medications used for ADHD, alongside stimulants and atomoxetine. |
South Africa Market Information
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Reg. No. 41/1.2/0373 | Voxra Xl 150 | Tablet (oral) | Not listed in the supplied data |
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Bupropion has a plausible mechanism, several completed ADHD studies, and a Cochrane review for adults. However, no Phase 3 trial that clearly tests bupropion could be confirmed from the supplied data, so the evidence stays at L2 rather than L1. The product is already marketed in South Africa, but its registered indication text in the data supplied is blank.
To proceed, the following is needed:
- Verify at the registry that bupropion was the test agent in NCT00048360 and NCT00061087, and extract their efficacy results. If both are confirmed, the evidence level could be reassessed toward L1.
- Obtain the SAHPRA package insert and extract its warnings and contraindications. This is a blocking gap before safety screening.
- Obtain detailed mechanism of action data from DrugBank.
- Set up guardrails: seizure-threshold caution, blood pressure and heart rate monitoring, and caution in patients with substance use or eating disorders.
- Position use as second-line or adjunct, mainly for patients who do not respond to or cannot tolerate stimulants.
- The other nine TxGNN predictions were not developed in this report. Rank 2 (ADHD, inattentive type) has indirect evidence only and is best assessed within the parent ADHD indication. Ranks 3–10 have no plausible mechanistic link or no evidence and should be held.
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.